Physician profile
Scott Svitek
NPI 1699854638
$1,127.09
in general payments reported to CMS, 2019-2025
15 companies · $134 in 2025
The $134 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.36 · 2020: $66.82 · 2021: $83.95 · 2022: $169 · 2023: $182 · 2024: $393 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $208.50 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Cranial Technologies, INC | $169.66 | 2020-2025 | Doc Band |
| Kaleo, INC. | $168.13 | 2019-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $127.64 | 2024 | |
| Sanofi Pasteur INC. | $100.32 | 2019-2024 | |
| Pfizer INC. | $75.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $54.96 | 2021-2025 | Bexsero |
| Cmp Pharma, INC. | $52.28 | 2023 | Norliqva |
| Astrazeneca Pharmaceuticals LP | $39.40 | 2022-2024 | Flumist Quadrivalent |
| Alk-Abello, INC | $36.46 | 2025 | Neffy |
| Ars Pharmaceuticals Operations, INC. | $24.20 | 2025 | Neffy |
| Seqirus USA INC | $21.06 | 2023 | Flucelvax Quadrivalent |
| Cumberland Pharmaceuticals, INC. | $17.61 | 2024 | Kristalose |
| Hologic Sales and Service, LLC | $17.12 | 2023 | Thinprep 2000 Processor |
| Aytu Biopharma, INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Svitek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.